GILEAD SCIENCES, INC. GILD revenue by segment, product and geography
In its fiscal year ending 2025-12-31, GILEAD SCIENCES, INC. reported revenue across 22 products and services; the largest, Product, was $28.9B (+1.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$28.9Bshare n/a+1.1% yoy
- HIV Product Sales$20.8Bshare n/a+5.8% yoy
- HIV Products Biktarvy$14.3Bshare n/a+6.8% yoy
- Oncology Product$3.24Bshare n/a-1.6% yoy
- Liver Disease$3.22Bshare n/a+6.5% yoy
- HIV Products Descovy$2.76Bshare n/a+30.5% yoy
- Cell Therapy Products Total Cell Therapy Product Sales$1.84Bshare n/a-6.8% yoy
- HIV Products Genvoya$1.5Bshare n/a-15.0% yoy
- +14 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$20.9B70.9%+1.4% yoy
- Europe$5.06B17.2%+9.3% yoy
- Rest of world$3.5B11.9%-0.7% yoy
Members sum to the consolidated $29.4B for this period.
- Product$6.95Bshare n/a+5.0% yoy
- HIV Product Sales$5.03Bshare n/a+9.7% yoy
- HIV Products Biktarvy$3.36Bshare n/a+6.7% yoy
- Oncology Product$810Mshare n/a+7.0% yoy
- HIV Products Descovy$807Mshare n/a+37.7% yoy
- Liver Disease$767Mshare n/a+1.2% yoy
- +18 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.